The potential biological effects of quercetin based on pharmacokinetics and multi-targeted mechanism<i>in vivo</i>
Adili Keranmu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jian‐Dong Jiang(Ningbo University), Li‐Bin Pan(Zhejiang Cancer Hospital), Ming-Shuai Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Nianzeng Xing(Chinese Academy of Medical Sciences & Peking Union Medical College), Siyiti Amuti(Xinjiang Medical University), Hang Yu(Humboldt-Universität zu Berlin), Yifang Liu(Xiamen University), Jie Fu, Zhengwei Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Feiya Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Pei Han(Chinese Academy of Medical Sciences & Peking Union Medical College), Hui Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Dong Chen(Nanjing University of Chinese Medicine), Yan Wang(National Institute of Biological Sciences, Beijing), Shurong Ma(Dalian Medical University)
Cited by 9
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
|Cancer Cell|2005|368
Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson’s disease by regulating gut microbiota
|Signal Transduction and Targeted Therapy|2021|315